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MéxicoA B S T R A C TObjective: Few patients with asthma have disease that is well-
controlled, particularly in Latin American countries. The purpose of
this study was to investigate whether partly controlled and uncon-
trolled asthma are associated with increased costs for asthma-related
medications and health care utilization compared with well-
controlled asthma in ﬁve Latin American countries. Methods: Using
the Global Initiative for Asthma guidelines, we classiﬁed respondents
from the Latin American Asthma Insights and Management
survey into those with well-controlled, partly controlled, and uncon-
trolled asthma and compared the utilization of health care services
and costs among these groups. Results: Most respondents to
our survey (93%) had asthma that was classiﬁed as partly controlled
or uncontrolled. Across all countries, patients whose asthmaee front matter Copyright & 2014, International S
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9455, Seattle, WA 98195.was partly controlled or uncontrolled had greater use of asthma-
related medications and medical services than did patients
whose asthma was well-controlled. After adjusting for age, sex, and
country of residence, total costs for asthma-related medications and
health care were greater in patients whose asthma was classiﬁed as
partly controlled and uncontrolled. Conclusions: Our ﬁndings indi-
cate that patients with asthma that are not well-controlled used more
health care resources and had greater medical costs in Latin America.
Keywords: Global Initiative for Asthma (GINA) guidelines, health care
utilization, hospitalization, long-term maintenance medications, oral
steroids.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Approximately 40 million patients with asthma reside in Latin
American countries and although data are sparse, the prevalence
of asthma in most of these countries is believed to be increasing
[1,2]. In addition, mortality rates from asthma are higher in Latin
American countries than in other regions [2,3]. Asthma is also a
signiﬁcant cause of missed school and work in Latin America [4].
Although medications that have been shown to be highly effec-
tive at managing asthma have been available since the 1990s [5],
most of the patients do not have well-controlled asthma, partic-
ularly in Latin American countries [6]. Although few studies have
examined the costs of asthma in Latin America, evidence indi-
cates that poorly controlled asthma in Latin America leads to
signiﬁcant economic expenditures, most of which have been
attributed to emergency and unscheduled health care sought by
patients with severe persistent asthma [6].
Over the past decade, measurements of asthma control,
rather than metrics of lung function such as forced expiratory
volume in 1 second, have been introduced to characterizemorbidity of patients with asthma because objective physio-
logical measures have been shown to have little correlation
with health-related quality of life [7,8]. Instead, the Global
Initiative for Asthma (GINA) and the United States National
Asthma Education Prevention Program have created guidelines
focused on regulating asthma symptoms to maintain normal
daily activity levels [9,10]. We recently conducted a US study
that demonstrated that asthma that is deﬁned as not well-
controlled by GINA guidelines is associated with increased rates
of adverse outcomes than is asthma that is classiﬁed as well-
controlled [11] and found similar results using data from Latin
America [12]. The purpose of this study was to investigate
whether partly controlled and uncontrolled asthma in ﬁve Latin
American countries (Argentina, Brazil, Mexico, Puerto Rico, and
Venezuela, which comprise about 65% of the population of
Latin America) were associated with increased costs due to
asthma medications, as well as asthma-related utilization of
health care services such as hospital admissions, emergency
room visits, and visits with health care providers, than was
asthma classiﬁed as well-controlled.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Latin America Asthma Insights and Management Survey
The Latin America Asthma Insights and Management (LA AIM)
survey [12,13] was designed to complement the US AIM survey
and was conducted in 2011. Both the US and LA AIM surveys
followed the methodology used in the Allergies in America
survey, which was designed by physician experts from various
regions who reviewed and approved survey questionnaires [14].
Subjects of the survey included in our analyses were 2168
patients with asthma aged 12 years or older identiﬁed from a
sample of 51,208 households in Argentina, Brazil, Mexico, Puerto
Rico, and Venezuela. These countries were selected because
preliminary data indicated that the size of the asthma population
in these countries was substantive enough to obtain sufﬁcient
sample sizes for analysis. Participants were selected randomly
using national probability sampling by survey organizations
based in each country [15]. Interviews were conducted in person
and averaged 35 minutes in length. For subjects aged between 12
and 17 years, the survey was completed by a parent or guardian.
The 53 survey questions were designed to assess asthma burden
(short- and long-term symptoms, functional impact, and health
care utilization such as provider visits and use of asthma
medications) and patient beliefs on appropriate use of medica-
tions for asthma control. In addition, demographic variables,
such as sex, age, education level, and diagnosis of nasal allergies,
were queried [15].
Classiﬁcation of Asthma Control
Patients were characterized on the basis of GINA guidelines [9]
into three categories of level of asthma control: well-controlled,
partly controlled, and uncontrolled (see Table 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2014.06.007).
The manifestations of asthma that were used for the categoriza-
tions included daytime symptoms, restriction of daily activities,
nighttime symptoms, and need for reliever/rescue treatment. We
used questions from the surveys that correlated with the GINA-
deﬁned asthma manifestations, with the exception of a lung
function measurement of less than 80% predicted, because lung
function measurements were not queried.
Statistical Analysis
Respondents to the survey provided data on the number of times
they took oral steroids, inhalers for quick relief/rescue, and long-
term maintenance medications for the management of asthma
symptoms in the previous 12 months. They also reported the
number of times they visited the emergency room, their health
care providers, or were hospitalized for asthma symptoms in the
past 12 months. Finally, respondents reported the number of
days they missed school or work in the past year. This article
evaluated total costs (e.g., payer, provider, and patient out-of-
pocket costs) that could be attributed to each asthma-related
medication and health service encounter. In Brazil, costs were
determined from Simpro, a Brazilian company that collects and
publishes the prices of medical costs that are released by the
governmental Agencia Nacional de Vigilância Sanitária [16], and
KairosBrasil, an aggregator of pharmaceutical dosing and cost
data in Brazil [17]. In Argentina, costs were obtained from
consultations with expert physicians and pharmacists. In Mexico,
costs were obtained by contacting Hospital Infantil de Mexico
Federico Gomez, Hospital Medica Sur, and Farmacia del Ahorro.
Because Puerto Rico is an unincorporated territory of the United
States and costs of drugs and health services are tied to Centers
for Medicare & Medicaid Services reimbursement rates, we used2011 Centers for Medicare & Medicaid Services reimbursement
rates [18], adjusted for the Puerto Rico geographic pricing cost
index, to calculate Puerto Rican costs. In Venezuela, costs were
obtained from the Hospital de Clinicas Caracas and by visiting
local pharmacies. Because costs varied substantially for patients
treated in the public versus the private sector, unit costs were
weighted by the proportion of patients with access to public/
private health care in each country. To estimate the cost of days
of missed work or school, we calculated the average income per
day for each country by dividing the yearly average annual
income by 240, the approximate number of working days per
year. Only those respondents who were employed or younger
than 18 years (assuming that a parent had to miss work to care
for a child who missed school because of asthma) at the time of
the survey were included in the analysis of the relationship
between the level of asthma control and missing school or work.
To allow comparison of costs between countries, all currencies
were converted to US dollars using the exchange rates as of
November 1, 2013. Mean annual costs for each medication/
utilization were calculated by multiplying the average unit costs
by the number of instances of utilizations in the previous 12
months reported by each AIM survey respondent. Finally, we
totaled each participant’s reported costs for all medications and
instances of utilization over the previous 12 months to obtain the
total mean annual direct costs of asthma care.
Frequencies and chi-square tests (or Fisher exact test when
the n of any cell was o5) were calculated for demographic
variables such as age, sex, and level of education. Next, differ-
ences by GINA-deﬁned level of asthma control in rates of
utilization of asthma-related medications, use of health care
services, and missed days of school and work were examined.
We calculated adjusted costs using negative binomial regression,
controlling for age and sex. To test the appropriateness of using
negative binomial regression, we examined the ratio of each
model’s deviance to the degrees of freedom. Because all ratios
were approximately 1, we assumed that the models ﬁt the data
well [19]. Because variables, particularly costs, tended to vary
widely by country of residence, all analyses were stratiﬁed on
country. Analyses were conducted using SAS for Windows,
version 9.3 (SAS Institute, Inc., Cary, NC).
This study was determined not to meet the federal regulatory
deﬁnition of human subjects’ research and hence was exempt
from Human Subjects review by the University of Washington
Institutional Review Board.Results
Demographic characteristics of the respondents to the AIM
survey, stratiﬁed on level of asthma control, are presented in
(see Table 2 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.vhri.2014.06.007). The greatest proportion of patients
with well-controlled asthma were in Brazil (9.3%) and Mexico
(9.0%); only 3% of the patients in Venezuela had well-controlled
asthma. In Brazil and Puerto Rico, respondents in the older age
categories tended to have partly controlled and uncontrolled
asthma compared with younger respondents. In all countries,
males were more likely than females to have well-controlled
asthma but the difference was statistically signiﬁcant only in
Argentina, Brazil, and Puerto Rico. In all countries, greater
education was associated with greater proportions of well-
controlled asthma but this relationship was statistically signiﬁ-
cant only for respondents from Brazil.
Next, we examined the mean number of times that respond-
ents used asthma medications and health care services pertain-
ing to their asthma, stratiﬁed on level of asthma control (see Fig.
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
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characterized as uncontrolled had statistically signiﬁcantly
greater frequency of asthma medication (oral steroids, inhalers
for quick relief/rescue, and long-term maintenance medicines)
use as well as visits to the emergency room and health care
providers than did patients whose asthma was well-controlled.
Relative to patients with well-controlled asthma, we observed
statistically signiﬁcantly increased hospitalizations in patients
with partly controlled and uncontrolled asthma in Argentina,
Brazil, Mexico, and Puerto Rico, but in Venezuela, the respond-
ents with well-controlled asthma had the greatest mean number
of hospitalizations. In all countries, we observed statistically
signiﬁcant trends of increased missed school or work with
decreased level of asthma control.
The mean costs, converted to US dollars, of each asthma-related
medication and health care service in each country for each level of
asthma control are presented in Table 3 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.vhri.2014.06.007. Costs were gen-
erally highest in Argentina and Puerto Rico and lowest in Brazil,
Mexico, and Venezuela. In all countries, we observed signiﬁcant
trends of increasing costs of oral steroids, inhalers for quick relief/
rescue, and long-term maintenance medication for decreasing level
of asthma control. We also observed statistically signiﬁcant trends
of increasing costs of emergency health care and health care
provider visits and costs of missing school or work in all countries.
In all countries except Venezuela, costs of hospitalizations were
also statistically signiﬁcantly greater with decreasing level of
asthma control. The greatest absolute differences in cost were seen
for missed school/work (e.g., a patient with well-controlled asthma
in Argentina cost an average of $12/y of missed school/work
compared with $2600/y for a patient with uncontrolled asthma)
and for hospitalizations (a patient with well-controlled asthma in
Brazil had mean costs of $40/y for hospitalizations compared with
$710/y for a patient with uncontrolled asthma). Total adjusted costs
for queried asthma-related medications and services and missed
school/work showed signiﬁcant trends by decreasing level of
asthma control in all countries (data not shown).Discussion
This study demonstrated that Latin American patients whose
asthma was characterized as partly controlled or uncontrolled
reported using asthma-related medications and health care
services and missing school/work at greater rates and had greater
costs of care for their asthma than did patients whose asthma
was characterized as well-controlled. This study indicates that
asthma that is not well-controlled creates a signiﬁcant cost
burden in Latin American countries and successful interventions
that could be taken to manage asthma more effectively might
result in cost savings for these countries. Examples of such
interventions include reducing the costs of asthma medications
to increase patient adherence to medication regimens, which
would likely decrease costly health care utilizations such as
unscheduled provider visits and hospitalizations, improving
training of health care providers, and providing information
and education to patients and their caregivers to improve self-
management of asthma [4]. Although multiple studies in devel-
oped countries have shown that these types of interventions are
cost-effective (see Labre et al. [20] for review), further research is
needed to determine whether they would be cost-effective in
Latin American countries.
The LA AIM survey was similar in design to the Asthma
Insights and Reality in Latin America survey, conducted in 10
Latin American countries (including Argentina, Brazil, Mexico,
and Venezuela) in 2003 [6,21]. One publication using data from
this survey used 2003 GINA guidelines to classify the level ofasthma control by symptom severity using patient-reported
asthma manifestations such as daytime and nighttime symp-
toms, exercise-induced symptoms, and total symptom severity
and also found that more severe forms of asthma were associ-
ated with signiﬁcantly greater costs compared with mild inter-
mittent asthma symptoms [6]. In addition, we conducted a
similar analysis of the costs of asthma medications and health
care utilization among US patients and determined that patients
with asthma that was not well-controlled used more health care
resources and had substantially greater medical costs than did
patients whose asthma was classiﬁed as well-controlled (among
patients with well-controlled asthma, mean annual asthma-
related costs were $750 compared with $4140 for patients with
uncontrolled asthma) [22]. Finally, an article by Sullivan et al. [23]
compared costs among patients with controlled and uncontrolled
asthma, characterized using guidelines from the Gaining Optimal
Asthma Control study [24], and found that costs for patients
whose asthma was uncontrolled were more than twice the costs
for patients whose asthma was controlled.
Although our study included a large population of Latin
American patients with asthma, it had several limitations.
Because we did not have data on nonrespondents, we cannot
be sure that those who agreed to take part in the survey were
representative of the Latin American population of patients with
asthma and results of this analysis might not be generalizable. In
addition, we did not sample in all Latin American countries and
notably did not include the populous countries Columbia, Chile,
or Peru, so we cannot be sure that our results are generalizable to
other Latin American locations. In some countries surveyed,
ofﬁcial costs of asthma medications and health services are not
available, so we made every effort to obtain accurate estimates of
costs by contacting representative health care delivery systems,
but actual costs may have varied. Although the wording of the
survey questions that we used to deﬁne well-controlled, partly
controlled, and uncontrolled asthma was similar to that used in
the GINA guidelines (see Table 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2014.06.007), it did not correlate
perfectly and our study population did not provide information
on forced expiratory volume in 1 second so we were not able to
use that information in our classiﬁcations. Also, our analyses
were based on self-reported information, which may have been
biased. Finally, although this article reports associations between
poorly controlled asthma and health care costs, the data were
cross-sectional and thus, we cannot address issues of causality in
this study.
Using a large population of Latin American patients with
asthma, this study demonstrated that the health care costs of
asthma that was not well-controlled were substantial in all the
ﬁve countries that were sampled. Steps to achieve control over
asthma symptoms, especially among patients belonging to com-
munities that lack access to quality care, would likely reduce the
clinical and economic burden of asthma in Latin America.Acknowledgments
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